Cargando…
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Pharmacology and Experimental Therapeutics
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148080/ https://www.ncbi.nlm.nih.gov/pubmed/30232095 http://dx.doi.org/10.1124/pr.117.015388 |
_version_ | 1783356694952148992 |
---|---|
author | Günther, Thomas Tulipano, Giovanni Dournaud, Pascal Bousquet, Corinne Csaba, Zsolt Kreienkamp, Hans-Jürgen Lupp, Amelie Korbonits, Márta Castaño, Justo P. Wester, Hans-Jürgen Culler, Michael Melmed, Shlomo Schulz, Stefan |
author_facet | Günther, Thomas Tulipano, Giovanni Dournaud, Pascal Bousquet, Corinne Csaba, Zsolt Kreienkamp, Hans-Jürgen Lupp, Amelie Korbonits, Márta Castaño, Justo P. Wester, Hans-Jürgen Culler, Michael Melmed, Shlomo Schulz, Stefan |
author_sort | Günther, Thomas |
collection | PubMed |
description | Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST(2) and SST(5) receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST(2) is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature. |
format | Online Article Text |
id | pubmed-6148080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The American Society for Pharmacology and Experimental Therapeutics |
record_format | MEDLINE/PubMed |
spelling | pubmed-61480802018-10-01 International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature Günther, Thomas Tulipano, Giovanni Dournaud, Pascal Bousquet, Corinne Csaba, Zsolt Kreienkamp, Hans-Jürgen Lupp, Amelie Korbonits, Márta Castaño, Justo P. Wester, Hans-Jürgen Culler, Michael Melmed, Shlomo Schulz, Stefan Pharmacol Rev IUPHAR Nomenclature Report Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST(2) and SST(5) receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST(2) is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature. The American Society for Pharmacology and Experimental Therapeutics 2018-10 2018-10 /pmc/articles/PMC6148080/ /pubmed/30232095 http://dx.doi.org/10.1124/pr.117.015388 Text en Copyright © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the CC BY Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | IUPHAR Nomenclature Report Günther, Thomas Tulipano, Giovanni Dournaud, Pascal Bousquet, Corinne Csaba, Zsolt Kreienkamp, Hans-Jürgen Lupp, Amelie Korbonits, Márta Castaño, Justo P. Wester, Hans-Jürgen Culler, Michael Melmed, Shlomo Schulz, Stefan International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
title | International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
title_full | International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
title_fullStr | International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
title_full_unstemmed | International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
title_short | International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
title_sort | international union of basic and clinical pharmacology. cv. somatostatin receptors: structure, function, ligands, and new nomenclature |
topic | IUPHAR Nomenclature Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148080/ https://www.ncbi.nlm.nih.gov/pubmed/30232095 http://dx.doi.org/10.1124/pr.117.015388 |
work_keys_str_mv | AT guntherthomas internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT tulipanogiovanni internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT dournaudpascal internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT bousquetcorinne internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT csabazsolt internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT kreienkamphansjurgen internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT luppamelie internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT korbonitsmarta internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT castanojustop internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT westerhansjurgen internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT cullermichael internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT melmedshlomo internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature AT schulzstefan internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature |